Provided by Tiger Trade Technology Pte. Ltd.

Dianthus Therapeutics Inc.

110.07
-1.0300-0.93%
Post-market: 110.070.00000.00%16:15 EDT
Volume:529.83K
Turnover:58.37M
Market Cap:6.16B
PE:-26.76
High:111.81
Open:110.08
Low:105.05
Close:111.10
52wk High:117.88
52wk Low:22.81
Shares:55.93M
Float Shares:55.87M
Volume Ratio:0.80
T/O Rate:0.95%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.1130
EPS(LYR):-4.2037
ROE:-26.07%
ROA:-17.69%
PB:5.25
PE(LYR):-26.18

Loading ...

Dianthus price target raised to $98 from $81 at Jefferies

TIPRANKS
·
Mar 10

Top Midday Gainers

MT Newswires Live
·
Mar 10

BUZZ-U.S. STOCKS ON THE MOVE-Hewlett Packard Enterprise, Dianthus, 3D Systems

Reuters
·
Mar 10

BUZZ-Dianthus jumps after nerve disease drug shows faster‑than‑expected response in trial

Reuters
·
Mar 10

Dianthus a ‘viable takeout target,’ says TD Cowen

TIPRANKS
·
Mar 10

Dianthus rises 26.3%

TIPRANKS
·
Mar 10

Dianthus price target raised to $130 from $47 at H.C. Wainwright

TIPRANKS
·
Mar 10

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (DNTH), Myomo (MYO) and Hims & Hers Health (HIMS)

TIPRANKS
·
Mar 09

Analysts Are Bullish on Top Healthcare Stocks: Dianthus Therapeutics (DNTH), Lantheus (LNTH)

TIPRANKS
·
Mar 09

Dianthus Shares Jump on Early Decision to OK CIDP Trial

Dow Jones
·
Mar 09

Dianthus price target raised to $110 from $63 at Truist

TIPRANKS
·
Mar 09

Dianthus Therapeutics FY 2025 net loss rises 91% to USD 162.34 million

Reuters
·
Mar 09

Dianthus Therapeutics Highlights Recent Business Achievements, Including Go Decision for Phase 3 Captivate Cidp Trial, and Reports Q4 and FY 2025 Financial Results

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Inc - Independent Dsmb Review Confirms Go Decision; No Related Serious Infections or Adverse Events

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Announces Early Go Decision Following Interim Responder Analysis in Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (Cidp)

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Inc - Maintains 300Mg/2Ml S.c. Q2w Dose; Plans to Remove 600Mg/4Ml S.c. Q2w Arm

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics Inc - Expects to Provide Captivate Part B Top-Line Guidance by End of 2026

THOMSON REUTERS
·
Mar 09

Dianthus Therapeutics to Present Interim Phase 3 CAPTIVATE CIDP Trial Responder Results for Claseprubart

Reuters
·
Mar 09

Dianthus price target raised to $200 from $100 at Guggenheim

TIPRANKS
·
Mar 04

BRIEF-Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Mar 04